Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation

To compare efficacy between radical prostatectomy (RP), radiotherapy and observation with respect to overall survival (OS) in patients with clinically localized prostate cancer (PCa).

[1]  F. Montorsi,et al.  Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population‐based analysis , 2012, International journal of urology : official journal of the Japanese Urological Association.

[2]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[3]  B. Davies.  Prostate cancer: Lessons from PIVOT lost in media hype , 2012, Nature Reviews Urology.

[4]  I. Thompson,et al.  Prostate cancer--uncertainty and a way forward. , 2012, The New England journal of medicine.

[5]  Ronald C. Chen,et al.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. , 2012, JAMA.

[6]  Jens Hansen,et al.  Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. , 2012, European urology.

[7]  F. Montorsi,et al.  Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. , 2011, European urology.

[8]  W. Wheeler,et al.  Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. , 2011, American journal of epidemiology.

[9]  C. Simone.  Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95. , 2011, European urology.

[10]  Jack Hadley,et al.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. , 2010, Journal of the National Cancer Institute.

[11]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[12]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[13]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[14]  M. Cooperberg,et al.  Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. , 2007, The Journal of urology.

[15]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[16]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[17]  E. Small,et al.  Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. , 2006, The Journal of urology.

[18]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[19]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[20]  P. Nelson,et al.  Determining cause of death in prostate cancer: are death certificates valid? , 2001, Journal of the National Cancer Institute.

[21]  L. Walter,et al.  Cancer screening in elderly patients: a framework for individualized decision making. , 2001, JAMA.

[22]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[23]  C. Newschaffer,et al.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.

[24]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[25]  J. Feldman,et al.  Health service areas for the United States. , 1991, Vital and health statistics. Series 2, Data evaluation and methods research.

[26]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[27]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[28]  F. Montorsi,et al.  A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.

[29]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[31]  J. Newhouse,et al.  Econometrics in outcomes research: the use of instrumental variables. , 1998, Annual review of public health.

[32]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.